FIELD: chemistry.
SUBSTANCE: claimed invention relates to biodegradable water-insoluble polyethyleneglycol-based hydrogels. The claimed invention also deals with conjugates of such biodegradable hydrogels with affinity ligands or chelating groups or ion-exchange groups, bound with carriers of prodrugs, in which a biodegradable hydrogel in accordance with the claimed invention is the carrier, and their pharmaceutical compositions, as well as to their application as a drug. Described is a biodegradable water-insoluble poly(ethyleneglycol)-based hydrogel, containing fragments of the main chain, connected by hydrolytically degradable bonds, with fragments of the main chain being characterised by the molecular weight in the range from 1 kDa to 20 kDa and having the structure C*-(A-Hyp)x, where C* represents a branching core, A represents a polymer poly(ethyleneglycol)-based chain, Hyp represents a super-branched dendrite fragment, x represents an integer number from 3 to 15; and where the superbranched dendrite fragment additionally contains reactionable functional groups and connecting functional groups, with the fragments of the main chain being connected together by means of cross-linking fragments, and each cross-linking fragment has at least two hydrolytically degradable bonds at the end. A conjugate and a bound with the carrier prodrug, containing the said biodegradable hydrogel, and the application of the prodrug in a medication are also described. Also described are: a method of obtaining the said hydrogel, which includes a stage (a) reacting of a main chain reagent, and the hydrogel, obtained by the claimed method, in the form of a coating mesh, a stent or a microparticle, obtained by crashing by mechanical methods, such as mixing, breaking, cutting pressing or milling, and sieving in case of necessity.
EFFECT: disclosed are the methods of obtaining the prodrug, the method of obtaining the prodrug, injected through the needle, and the prodrug, obtained by the claimed method.
38 cl, 41 ex, 15 dwg
Title | Year | Author | Number |
---|---|---|---|
PRODRUGS CONTAINING EXENDIN CONJUGATE-LINKER | 2011 |
|
RU2593774C2 |
PRODRUGS CONTAINING INSULIN LINKER CONJUGATE | 2010 |
|
RU2574667C2 |
STERILISATION OF BIODEGRADABLE HYDROGELS | 2010 |
|
RU2558847C9 |
HYDROCARBON GEL-BASED PRODRUGS | 2013 |
|
RU2647729C2 |
DIAGNOSIS, PREVENTION AND TREATMENT OF JOINT DISEASES | 2013 |
|
RU2682676C2 |
PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON | 2016 |
|
RU2719482C2 |
VEGF NEUTRALISING PRODRUGS FOR THE TREATMENT OF OCULAR CONDITIONS | 2013 |
|
RU2673881C2 |
GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | 2007 |
|
RU2460543C2 |
DELAYED-RELEASE DELIVERY SYSTEMS CONTAINING TRACELESS LINKERS | 2018 |
|
RU2772690C2 |
LONG-ACTING INSULIN COMPOSITION | 2010 |
|
RU2556340C2 |
Authors
Dates
2015-06-27—Published
2010-07-30—Filed